Q1 2025 Management View Mike Exton, Chief Executive Officer, highlighted a pivotal exclusive license agreement with Novo Nordisk for LX9851, stating "this agreement grants Novo an exclusive worldwide ...

A pronouncement from President Trump about the category drove their share prices down, although not to bargain-basement ...

It's likely that Trump was referring to Elon Musk in the quoted tweet. Musk has publicly admitted to using weight-loss drugs ...

Analysts are still crunching the numbers on the impact of President Donald Trump's executive order from Monday on drug pricing. HSBC analyst Rajesh Kumar says a 20% price cut in government channels ...

It would be another two years before French researchers would identify a retrovirus as the cause of AIDS, or acquired immunodeficiency syndrome, according to the CDC. It would be another three years ...

The president claimed his “most-favored nation” proposal would reduce some pharmaceutical prices by as much as 80%, but the ...

The Kassø eMethanol facility in Aabenraa, Denmark, has been officially inaugurated and is now supplying eMethanol to ...

Tirzepatide conferred significantly greater weight loss than semaglutide at 72 weeks for adults with overweight or obesity, ...

With a late-stage trial win for its Norditropin heir in hand, Novo Nordisk is making good on plans to boost its profile in ...

Viking Therapeutics became famous in the biotech world last year after announcing positive phase 2 results for VK2735, an investigational GLP-1 weight loss candidate. The stock has not performed well ...

The world's first commercial-scale e-methanol plant began operations in Denmark on Tuesday, with shipping giant Maersk set to ...

People taking Eli Lilly's obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk's Wegovy in the first head-to-head study of the blockbuster medications. Clinical ...